and 10.2% (year 2) of patients, with the highest rate within the first 3 months for intolerance.
resistance (primary or acquired) and intolerance. 4, 5 Dose escalation of imatinib may be able to overcome resistance in some patients with CP-CML, however the duration of response is short-lived. [6] [7] [8] [9] [10] Therefore, second generation (2G) TKIs, which can effectively salvage these imatinib patients, are preferred. Based on the results of randomized controlled trials (RCTs) dasatinib (Sprycel, Bristol-Myers Squibb), nilotinib (Tasigna, Novartis), and bosutinib (Bosulif, Pfizer) have also been approved as first-line therapy. [11] [12] [13] Dasatinib, nilotinib, and bosutinib are associated with higher and faster rates of cytogenetic and molecular response as well as reduced rates of progression when compared with imatinib at 400 mg in the first-line setting, although an impact on survival has not been seen to date. [14] [15] [16] Complementary to the wealth of clinical trial data supporting the efficacy and safety of imatinib, dasatinib, and nilotinib, [15] [16] [17] [18] [19] observational studies contribute further insights to inform clinical decision making. 20 The circumstances under which initial TKI is selected, why it is discontinued and how a second-line TKI is chosen have been studied in the USA and Europe. However, most of these studies have a predominance of patients on first-line imatinib, 21, 22 despite the fact that use of the 2G TKIs in the first-line setting has increased in recent years. 23 Data collected from routine clinical practice indicate that up to one-third of patients on first-line imatinib undergo a change in treatment, including dose modification, treatment interruption, discontinuation or switch to another TKI, although this proportion may be higher. 22, 23 The main objective of the ongoing observational study 
| METHODS
The design of SIMPLICITY has been described in detail previously. 24 The TKI cohorts were closed when each had enrolled approximately 400 CP-CML patients receiving first-line therapy with imatinib, dasatinib, or nilotinib. The choice of TKI therapy was left to the discretion of the physician. Study sites in the USA and Europe including Russia include academic (defined as large, hospital-based clinics or research units at universities, including specialized centers of excellence, offering care on a regional/national basis) and private/community practices (defined as small, private practices run by one or more independent physicians offering patient care on a local basis). The study protocol was approved by the relevant institutional review boards and written patient consent obtained.
Treatment interruption was defined as a gap in treatment of >1 day before restarting the same TKI, from the day the TKI was temporarily discontinued and ending the day before restarting. Treatment discontinuation was defined as cessation of TKI treatment that did not qualify as a treatment interruption; switch was defined as discontinuation of index TKI, followed by start of second-line TKI during the follow-up period. All patients who switched TKI treatment were considered as having discontinued therapy. Treatment interruptions and discontinuations were analyzed according to the date of TKI discontinuation and TKI switch, according to the date of second-line TKI start. Treatment interruptions and discontinuations were grouped according to whether they occurred within 1 year of index TKI initiation (first year of therapy) or between 1 and 2 years after index TKI initiation (second year of therapy).
Reasons for TKI changes were reported; choices were intolerance; primary resistance (failure to achieve a response) 3 (Table 2 ). and gastrointestinal (GI) disorders (n = 40) were the most common types of intolerances related to treatment discontinuation (Table 3) .
| Treatment discontinuations
Specific intolerances leading to TKI discontinuation were rash (n = 9)
in the imatinib group, pleural effusion in the dasatinib group (n = 11), and rash (n = 8) in the nilotinib group.
Resistance was the second most common reason for discontinuation of first-line TKI, reported in 22 (9.4%) patients and occurring in 16 patients receiving imatinib, 3 patients receiving dasatinib and 3 patients receiving nilotinib.
A multivariable logistic regression model identified that female patients were more likely than male patients to discontinue TKI therapy in the first year of treatment (odds ratio [OR] = 1.72, 95% CI:
1.29-2.31; P < .001). No significant differences were found in reasons for discontinuation between male and female patients (P > .05).
Patients treated with imatinib were more likely to discontinue therapy than patients treated with dasatinib (OR = 1.73, 95% CI: 1.21-2.47; P = .002).
| Treatment switching
Switching to second-line TKI after discontinuing first-line TKI in the first year of treatment was reported in 17.8% (n = 200) of patients ( Figure 1C ). The TKI most commonly switched from was imatinib (n = 96), followed by dasatinib (n = 53) and nilotinib (n = 51). The TKI most commonly switched to was dasatinib (n = 89), followed by imatinib (n = 54) and nilotinib (n = 53); patients also switched to bosutinib (n = 2) and ponatinib (n = 2). Of patients discontinuing dasatinib, twice as many patients switched to imatinib than nilotinib (n = 34 vs 17) ( Figure 1D ). Of patients discontinuing nilotinib, more switched to dasatinib than switched to imatinib (n = 30 vs 20)
( Figure 1D ). The overall number of patients switching from a 2G
TKI to imatinib was slightly higher than the number of patients switching from a 2G TKI to another 2G TKI (n = 54 vs 47). More patients discontinuing imatinib switched to dasatinib than nilotinib (n = 59 vs 36) ( Figure 1D ). For all patients, and for each TKI, slightly higher proportions of patients switched therapy within 0-3 months of treatment than in later periods ( Figure 1C ).
Intolerance was the most common reason for switching of firstline TKI in the first year of treatment, reported in 146 patients. The most common types of intolerance leading to switching were GI disorders (n = 37) ( Table 3 ). In the imatinib group, the most common types of intolerance leading to switching were GI and musculoskeletal and connective tissue disorders (n = 16 each). In the dasatinib group, the most common intolerance leading to switching were respiratory disorders (n = 14). In the nilotinib group, the most common intolerance leading to switching were GI disorders (n = 13). Specific intolerances most commonly leading to TKI switching were rash in the imatinib and nilotinib groups (n = 9 and 7, respectively) and pleural effusion in the dasatinib group (n = 8). is possible that these patients moved to another medical center, chose to discontinue from the study, progressed beyond CP-CML or died.
A multivariable logistic regression model identified that female patients were more likely than male patients to switch TKI therapy in a General disorders and administration site conditions includes asthenia, chest pain, chills, discomfort, edema, fatigue, influenza-like illness, malaise, mucosal inflammation, pain, pyrexia, and swelling.
the first year of treatment (OR = 1.69, 95% CI: 1.23-2.32; P = .001).
Patients treated with imatinib were more likely to switch therapy than patients treated with dasatinib (OR = 2.28, 95% CI: 1.56-3.35; P < .001). Table 2 ). Fewer treatment interruptions occurred than in the first year of follow-up, and the events concurrent with interruptions differed. A multivariable logistic regression model identified that female patients were less likely than male patients to discontinue TKI therapy in the second year of treatment (OR = 0.50, 95% CI: 0.33-0.77; P = .001).
|

| Treatment discontinuations
No significant differences were found in reasons for discontinuation between male and female patients (P > .05). Patient age of ≥65 years at diagnosis was associated with TKI discontinuation (OR = 1.66, 95% CI:
1.06-2.60; P = .026); this association was seen for patients treated with imatinib (OR = 2.88, 95% CI: 1.38-5.97; P = .005), but not for those treated with dasatinib or nilotinib. Patients treated with dasatinib who had an ECOG score of 1-4 at baseline (corresponding to restricted strenuous activity through to completely disabled) were more likely to discontinue treatment than those with an ECOG score of 0 (OR = 2.86, 95% CI:
1.21-6.72; P = .016). This was not seen for the overall population or for other TKI groups.
| Treatment switching
In the second year of follow-up, switching to a new TKI after discontinuing first-line TKI was observed in fewer patients than in the first year, with 9.5% (n = 107) of patients switching ( Figure 3A) . The TKI most commonly switched from was imatinib (n = 43), followed by dasatinib (n = 36) and nilotinib (n = 28). The TKI most commonly switched to was dasatinib (n = 44), followed by nilotinib (n = 35) and imatinib (n = 18); patients also switched to bosutinib (n = 3) and ponatinib (n = 7). Of patients discontinuing dasatinib, more switched to nilotinib than to imatinib (n = 18 vs n = 12) and more patients discontinuing nilotinib switched to dasatinib than to imatinib (n = 19 vs 6) ( Figure 1D ). The total number of patients switching from one 2G TKI to another 2G TKI was greater than the number of patients switching from a 2G TKI to imatinib (n = 37 vs 18). More patients discontinuing imatinib switched to dasatinib than nilotinib (n = 25 vs 17)
( Figure 1D ).
Intolerance was the most common reason for switching of firstline TKI in the second year of treatment (n = 54). The most common types of intolerance were respiratory, thoracic and mediastinal disorders (n = 17) and GI disorders (n = 12) (Table 3) . Respiratory, thoracic and mediastinal events were mainly seen with dasatinib, mostly from pleural effusion (n = 13).
Primary resistance was the second most common reason for switching of first-line TKI (n = 30). Most patients developing resistance were treated with imatinib (n = 19), but resistance was also reported with dasatinib and nilotinib (n = 4 and 7, respectively). Mutation of ABL kinase was investigated in 107 patients in the second year, and a known ABL kinase mutation was observed in 11 patients prior to switching to second-line TKI in the second year of therapy.
Of 114 patients who discontinued treatment in the second year, 107 switched TKI within the second year and 4 switched after 2 years.
Therefore, 3 patients did not switch to a different TKI. Reasons for discontinuation without switching were not collected prospectively.
A multivariable logistic regression model identified that, in the second year of follow-up, patient age of ≥65 years at diagnosis was associated with TKI switching (OR = 1.66, 95% CI: 1.05-2.61; P = .029).
Patients treated with dasatinib who had an ECOG score of 1-4 at baseline (corresponding to restricted strenuous activity through completely disabled) were more likely to switch treatment than those with an ECOG score of 0 (OR = 5.02, 95% CI: 1.96-12.85; P = .001). This was not seen for the overall population or for other TKI groups. 
| DISCUSSION
28-30
Just over one-sixth of patients switched TKI in their first year of treatment and just under one-tenth in their second year of treatment.
In the first year, a greater proportion of patients switched from imatinib than from a 2G TKI, but in the second year, the numbers of patients switching were similar across TKIs. The main reason for discontinuation and switching therapy in the first and the second years of treatment was intolerance, followed by primary resistance.
The intolerances observed in SIMPLICITY were in line with those known for imatinib, dasatinib, and nilotinib. [15] [16] [17] [18] [19] However, TKIspecific late intolerance was observed in some situations. In patients treated with imatinib, for example, the number of patients discontinuing for GI disorders in the second year was greater than for other TKIs (Table 3) . Furthermore, in patients treated with dasatinib, the number of patients discontinuing owing to respiratory, thoracic and mediastinal disorders, especially pleural effusion, in the second year was similar to that in the first year and greater than seen for other TKIs (Tables 3 and 4 ). In the case of dasatinib, this is likely to be at least partly related to the fact that pleural effusion is noted to potentially occur steadily throughout exposure rather specifically within an early/ late timeframe as seen with other observed intolerances. For patients treated with nilotinib, the frequency of intolerances associated with discontinuation and/or switching were comparable in the first and second years (Tables 3 and 4 ). The findings from SIMPLICITY indicate that management of intolerances remains an issue in clinical practice, and that these intolerances frequently result in discontinuation of TKI therapy. There is a continued need for effective management of intolerances, as well as for a range of treatment options available to switch between to suit the needs of patients.
Primary resistance played a much smaller part in dictating treatment patterns than intolerance. Consistent with previous reports, discontinuation owing to resistance in SIMPLICITY was most commonly observed with imatinib. 31 Resistance may have been underestimated due to suboptimal monitoring; we have previously reported that, in the US and Europe, a significant proportion of CP-CML patients do not undergo cytogenetic or molecular monitoring as recommended by guidelines, which if performed would identify early resistance indicating need for switching. 24 The increased frequency of switching due to primary resistance in the second year is consistent with resistance occurring later in treatment, after intolerances have manifested. This suggests a shift in the predominant "driver" of switch over time, from intolerance to resistance. Clinical guidelines advocate switching of TKI if clinical response is inadequate at 3, 6, and 12 months, but are more conservative about switching due to intolerance. 2, 3 However, data from SIMPLICITY suggest that in routine clinical practice a decision to switch TKI may be based on considerations beyond those specified in clinical guidance. 27 The demographics of SIMPLICITY patients are similar to those of patients in clinical trials supporting imatinib, nilotinib, and dasatinib, with the exception of median patient age (56.5 years), which is older than in these trials and 3 others that studied imatinib. 17, 18, [32] [33] [34] The demographics of patients in SIMPLICITY (including age) are closer to those in other observational studies, including the European Treatment and Outcome Study (EUTOS) CML registry. 21 A systematic review has indicated that, in newly diagnosed and untreated elderly patients, age does not generally play a great part in determining clinical response to TKIs. 35 In SIMPLICITY, significant associations were found between patient age ≥65 years and both discontinuation and switching of a TKI in the second year of treatment. Furthermore, these associations were found for patients receiving imatinib, but not dasatinib or nilotinib. The main reason for discontinuation and switching was intolerance, and it may be tempting to attribute the observed associations to increased likelihood of intolerances in older patients. It may be that primary resistance to imatinib is also an important driver in elderly patients in SIMPLICITY, although this is inconsistent with observations from other studies reporting that imatinib resistance occurs at similar rates in younger and older populations. 36, 37 These observations may warrant a deeper investigation into the impact of age in the SIMPLICITY population, in which approximately one-third were over 65 when TKI therapy was initiated.
One value of observational research is that it includes a broader patient population than that included in RCTs. 20 However, the nonrandomized design of observational studies means there is a risk of selection bias and confounding; results should thus be interpreted in the context of clinical practice and any comparisons with results from
RCTs made with caution. 20, 38 Some of the specific limitations of the SIMPLICITY study around patient enrolment, availability of TKIs and monitoring have been discussed previously and remain relevant here. 24 Limitations specific to this particular analysis include the fact that intolerances were not graded, so it is not possible to understand if severity of an intolerance played a role in TKI discontinuation. Also, caution must be exercised when drawing conclusions over reasons for TKI switching, as these were not prospectively recorded, which means that hypotheses on this are difficult to test. Switching patterns with TKIs may also be reflective of the changing CML treatment landscape; as reported previously, there was a shift from the use of imatinib to 2G TKIs in the SIMPLICITY population from 2009 to 2015, a shift that is exaggerated given enrollment into the imatinib cohort was completed earlier than for the dasatinib and nilotinib cohorts. 24 The link between TKI discontinuations and switching is currently being explored and will be reported elsewhere.
Analysis of data from the first 2 years of treatment in SIMPLICITY indicates that intolerance, and to a lesser degree resistance, influence the TKIs that CML-CP patients receive. Age and gender may be implicated in the ability of patients to tolerate TKIs. Further follow-up may elucidate whether these and other variables impact the ability of patients to remain on specific TKIs long-term or whether late side effects emerge that might influence treatment.
